CSL (ASX:CSL) said it will transition its US plasma collection centers to Haemonetics' latest-generation plasmapheresis platform, with the rollout expected to be completed by the end of 2027, according to an Australian bourse filing on Thursday after market hours.

The company has also reached an agreement with Terumo BCT, the provider of its current Rika system, to ensure a smooth transition, the filing added.